JW Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

JW Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-425,755	Closed	-$21.5M	–	17
2019 Q1	$21.5M	Hold	425,755	–	–	11.04%	3
2018 Q4	$17.2M	Sell	425,755 -50,000	-11%	-$2.58M	12.64%	3
2018 Q3	$33M	Hold	475,755	–	–	17.8%	3
2018 Q2	$36M	Hold	475,755	–	–	22.95%	2
2018 Q1	$25.1M	Hold	475,755	–	–	24.71%	2
2017 Q4	$25.4M	Sell	475,755 -50,000	-10%	-$2.78M	27.04%	1
2017 Q3	$31.4M	Hold	525,755	–	–	22.97%	1
2017 Q2	$41.5M	Hold	525,755	–	–	26.41%	1
2017 Q1	$43.6M	Hold	525,755	–	–	9.08%	2
2016 Q4	$41.7M	Hold	525,755	–	–	27.76%	1
2016 Q3	$36.8M	Buy	525,755 +276	+0.1%	+$15.3K	25.34%	1
2016 Q2	$20.4M	Sell	525,479 -234,900	-31%	-$9.78M	16.2%	1
2016 Q1	$30.8M	Sell	760,379 -97,300	-11%	-$6.17M	20.11%	1
2015 Q4	$76M	Buy	857,679 +8,970	+1%	+$708K	28.38%	1
2015 Q3	$62.8M	Buy	848,709 +31,825	+4%	+$2.65M	22.76%	1
2015 Q2	$66.1M	Buy	816,884 +81,342	+11%	+$5.3M	20.08%	1
2015 Q1	$30.8M	Buy	735,542 +633,719	+622%	+$18M	13.32%	1
2014 Q4	$1.58M	Buy	+101,823	New	+$1.3M	1.18%	19

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JW Asset Management's EGRX Position: Q2 2019 in Review

JW Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 425,755 shares — an estimated $21.5M sold.

JW Asset Management first reported a position in EGRX in Q4 2014 and held it in 18 quarters. The position peaked at $76M in Q4 2015. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

JW Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
JW Asset Management sold 425,755 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $21.5M.
JW Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2014 and held it in 18 quarters.
JW Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $76M in Q4 2015.
180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on JW Asset Management's 13F filing for Q2 2019, filed 9 Aug 2019.